Replies to post #148716 on Biotech Values

[genisi]

I guess you're right on the "meta-analysis of a subgroup" issue, but perhaps an ADAS-Cog change of >=3 for solanezumab in the prespecified secondary analysis of pooled mild along with MRI and biomarkers, could give them a shot with the FDA considering the highly unmet need and the good safety profile. A 3 point change seems quite hypothetical though...